Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

11.01 +0.12 (+1.15%)
Streaming Delayed Price Updated: 11:54 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 19, 2025 ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Inc (NASDAQ:FOLD) Q3 2025 Earnings: A Landmark Quarter with Strong Profitability Beat ↗
Amicus Therapeutics (FOLD) beats Q3 2025 earnings estimates with strong revenue growth and a major milestone in profitability, driving positive market momentum. 
Via Chartmill
News headline image
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
Amicus (FOLD) Q2 Revenue Jumps 22% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading ↗
Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts ↗
 
Via Benzinga
News headline image
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics ↗
 
Via Benzinga
News headline image
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? ↗
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
News headline image
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug ↗
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 4 Takes On Amicus Therapeutics ↗
 
Via Benzinga
News headline image
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today. ↗
 
Via Benzinga
News headline image
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics Stock Sees Improved Relative Strength Rating ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily
News headline image
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps ↗
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on. 
Via InvestorPlace
Topics Bankruptcy
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.